Key result
Advanced imaging modalities, including echocardiography with strain, cardiac magnetic resonance, and PET, are recommended for risk assessment and early diagnosis of cardiovascular toxicity in cancer.
Why the study?
Increasing cancer treatments cause high rates of cardiovascular toxicities, making long-term monitoring difficult and requiring imaging modalities for risk assessment, detection, and early diagnosis.
What are the recommended imaging modalities for detecting and tracking cancer treatment-related cardiovascular dysfunction?
What are the recommended imaging modalities for detecting and tracking cancer treatment-related cardiovascular dysfunction?
This review highlights the role of advanced multimodality imaging in the early detection and monitoring of cardiovascular toxicities associated with cancer therapies.
New cancer therapies heighten CV toxicity risks in survivors; leaves open updated classification and multidisciplinary monitoring strategies.
Advances in cancer treatments have led to an increase in the number of cancer survivors, but also high rates of short-and long-term cardiovascular (CV) toxicities. The number of new cancer drugs is constantly increasing, and the increasing incidence of toxicities of these drugs make long-term care and monitoring difficult. Moreover, traditional type I and type II cardiotoxicities may not be applicable to all of these agents. Multidisciplinary care with expertise in oncology, cardiology and other related specialties is required to mitigate cancer therapeutics-related cardiovascular dysfunction (CTRCD). Accordingly, CTRCD should include all kinds of toxic/side effects affecting the CV system, including hypertension, endothelial and vascular dysfunction, accelerated atherosclerosis, thrombosis and bleeding, pulmonary hypertension, pericardial disease, QT prolongation, conduction disease/arrhythmias, as well as radiationinduced CV disease (CVD). This study reviews the currently recommended imaging modalities including advanced echocardiographic parameters including global longitudinal strain (GLS), left atrial strain (LAS), fast strain encoded cardiac magnetic resonance (CMR) imaging (fast-SENC) and T1 and T2 mapping, myocardial 18 F-fluorodeoxyglucose (FDG) uptake in heart positron emission tomography (PET) and computed tomography coronary angiography for risk assessment, detection and early diagnosis of CTRCD.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2021) conducted a review in Cancer therapeutics-related cardiovascular dysfunction (CTRCD). Advanced imaging modalities (echocardiography, CMR, PET, CT) was evaluated. Advanced imaging modalities, including echocardiography with strain, cardiac magnetic resonance, and PET, are recommended for risk assessment and early diagnosis of cardiovascular toxicity in cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: